IDEXX Laboratories, Inc. $IDXX Shares Sold by Bessemer Group Inc.

Bessemer Group Inc. reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.6% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 311,349 shares of the company’s stock after selling 40,919 shares during the quarter. Bessemer Group Inc.’s holdings in IDEXX Laboratories were worth $210,636,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in IDXX. Bank of New York Mellon Corp grew its position in IDEXX Laboratories by 41.7% during the third quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock worth $1,313,992,000 after buying an additional 605,290 shares during the period. JPMorgan Chase & Co. grew its position in IDEXX Laboratories by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock worth $555,802,000 after buying an additional 326,348 shares during the period. Zurich Insurance Group Ltd FI acquired a new position in IDEXX Laboratories during the third quarter worth about $143,730,000. AustralianSuper Pty Ltd lifted its holdings in shares of IDEXX Laboratories by 213.1% in the fourth quarter. AustralianSuper Pty Ltd now owns 300,197 shares of the company’s stock valued at $203,092,000 after purchasing an additional 204,307 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of IDEXX Laboratories by 16.7% in the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock valued at $840,638,000 after purchasing an additional 187,967 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $532.86 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The company has a market capitalization of $42.03 billion, a price-to-earnings ratio of 39.24, a PEG ratio of 3.08 and a beta of 1.58. The company’s 50 day simple moving average is $574.48 and its 200 day simple moving average is $646.38. IDEXX Laboratories, Inc. has a 1 year low of $496.61 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.66 EPS for the current year.

Analysts Set New Price Targets

IDXX has been the topic of several recent research reports. UBS Group reduced their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday. Citigroup initiated coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target on the stock. Finally, Barclays reduced their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

Insider Activity

In related news, EVP Michael G. Erickson sold 5,371 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the transaction, the executive vice president owned 12,693 shares of the company’s stock, valued at approximately $7,963,334.34. This represents a 29.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Sophie V. Vandebroek sold 1,464 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total transaction of $920,299.68. Following the transaction, the director directly owned 648 shares in the company, valued at $407,345.76. The trade was a 69.32% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 34,612 shares of company stock worth $22,525,070. 0.79% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.